SleepX seeks approval from Helsinki Committee for its clinical research with the SleepX PRO smartphone application
SleepX PRO is designed to diagnose sleep apnea using only a smartphone and without physical contact
Boca Raton, Florida – News Direct – Appyea
SleepX, a subsidiary of AppYean (OTC: APYPD) focusing on the development of accurate wearable monitoring solutions for the treatment of sleep apnea and snoring, announces that it has applied to the Helsinki Committee for permission to start a planned clinical trial with SleepX PRO.
This follows a recent update from the company that it plans to test SleepX Pro in a hospital unilaboratory. The experiment is the first step toward seeking FDA approval for the first non-contact detection of sleep apnea in a category of medical devices performed using artificial intelligence (AI) analysis of breathing during sleep. Because the request is submitted in the category of medical devices and the trial is contactless, the company expects the process to be fast and take up to a few months.
SleepX Pro, designed to diagnose sleep apnea using only a smartphone, does not require physical contact with the subject. According to a report by Grand View Research, the global sleep apnea device market is estimated to be $ 3.7 billion in 2020, with a CAGR of 6.2% and reaching $ 6.1 billion by 2028.
“Poor sleep is associated with a weakened immune system, heart problems, impaired physical and mental performance, mood problems, obesity and many other health problems,” said Neil Kline, founder and former CEO of the American Sleep Association and a board member of SleepX. “Unfortunately, most people with sleep-disordered breathing problems, such as sleep apnea, go undiagnosed and untreated. Our goal with this unique technology is to raise awareness of the problem and increase people’s awareness that they can live healthier and more fulfilling lives.”
“SleepX PRO is a unique, fast and friendly diagnostic tool that prevents subjects from having to spend nights in sleep labs, saving hundreds of millions of dollars for the healthcare system and insurance companies,” said Boris (Bary) Molchadsky, CEO of SleepX and Chairman of AppYea. “We’re going to make our diagnostic solution very easy to use so people can get tested easily.
SleepX is an Israeli research and development company recently acquired by AppYea. The company had developed a unique product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and the company plans to begin series production in 2022. The company is currently focusing on the development and commercialization of its flagship product DreamIT.
Legal notice on forward-looking statements
This bulletin contains forward-looking statements. Such statements contain risks and uncertainties that could cause actual results to differ materially from those set forth herein. Nothing herein should be construed as constituting an offer or solicitation to purchase or sell securities. Although APYP believes that the expectations and assumptions on which forward-looking statements are based are reasonable, it cannot provide assurance that such expectations and assumptions will prove to be correct. Forward-looking statements that make assumptions and describe our future plans, strategies and expectations are generally identifiable by the use of the words “may”, “will”, “should”, “could”, “anticipate”, “anticipate”, ” belief “,” time “or” project “or a negative word of these words or other variations of these words or similar terminology. The reader is cautioned not to have unreasonable reliance on these forward-looking statements, as these statements are subject to a number of factors and uncertainties, including, but not limited to, adverse economic conditions, fierce competition, entry of new competitors and products, harmful federal, state and municipal regulations. capital, unforeseen costs and operating deficits, increase in general and administrative expenses, unexpected losses, financial condition and share price, inability to implement research, development and commercialization plans, and other specific risks. APYP is not required to publicly update forward-looking statements. APYP and SLEEPX are not subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934, as amended.
Contact information
Asaf Porat
company website
See the source version at newsdirect.com: https://newsdirect.com/news/sleepx-applies-to-the-helsinki-committee-for-approval-on-its-clinical-trial-with-the-sleepx-pro-smartphone-application-460004951